Sabzevari Helen 4

What Happened

• Helen Sabzevari, President & CEO and director of Precigen (PGEN), was granted 321,100 restricted stock units (RSUs) on 2026-03-18 that vested immediately and were converted to 321,100 shares. The award is reported at $0.00 per share (derivative award). The Form 4 also shows a concurrent conversion/exercise and a disposition entry for 321,100 derivative shares at $0.00; the filing does not report cash changing hands.

Key Details

• Transaction date: 2026-03-18. Form 4 filed: 2026-03-20 (appears timely).
• Grant: 321,100 RSUs @ $0.00 (reported as award/acquisition).
• Conversion/Exercise: 321,100 derivative units converted to shares (code M).
• Disposition: 321,100 derivative units listed as disposed at $0.00 in the same reporting line.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — each RSU equals a contingent right to one share; F2 — RSUs vested immediately upon grant.
• Filing timeliness: Reported two days after the transaction date (within the usual Form 4 reporting window); filing does not indicate lateness.

Context

• RSUs are a common form of executive compensation; they represent a right to receive company shares when they vest. In this case the RSUs vested immediately and were converted to shares. The filing shows both the award/acquisition and a corresponding conversion/disposition at $0.00; the Form 4 does not specify the reason for the zero-dollar disposition (e.g., tax withholding, settlement mechanics, or transfer). These administrative mechanics are different from an open-market purchase or sale and should be interpreted accordingly.